Skip to content

PRESS RELEASE | Minister for Health approves addition of Congenital Adrenal Hyperplasia (CAH) to National Newborn Bloodspot Screening Programme

Press Release: Friday 13 November 2026

Under embargo until 00:01 Saturday 14 November 2026

Minister for Health approves addition of Congenital Adrenal Hyperplasia (CAH) to National Newborn Bloodspot Screening Programme

The Minister for Health, Jennifer Carroll MacNeill TD, has approved a recommendation from the National Screening Advisory Committee (NSAC) to add Congenital Adrenal Hyperplasia (CAH) to the National Newborn Bloodspot Screening Programme.

Welcoming the recommendation, Minister Carroll MacNeill said:

“The National Screening Advisory Committee’s recommendation to add Congenital Adrenal Hyperplasia (CAH) to the National Newborn Bloodspot Screening Programme is an important step in expanding newborn screening in Ireland.

“CAH is a rare but serious condition. Early diagnosis can make a significant difference for affected children and their families. Screening has the potential to help identify and treat the condition earlier, reducing the risk of serious complications.

“I am grateful to the National Screening Advisory Committee, its Newborn Bloodspot Screening Subgroup and the Health Information and Quality Authority (HIQA) for their detailed assessment of this proposal and their expert advice.

“I have now written to the Health Service Executive (HSE) asking it to begin planning the rollout of screening for CAH.”

The recommendation follows a comprehensive health technology assessment, which reviewed the evidence on screening for CAH. Screening decisions are guided by strong scientific evidence and international best practice.

The Minister added:

 “The expansion of newborn screening remains a priority for me and is reflected in both the Programme for Government and the National Rare Disease Strategy. It is one of the most successful public health programmes in our health service. Every newborn baby in Ireland, between three and five days of age, is offered screening for a range of rare but serious conditions. Early diagnosis of these conditions can make a significant difference to a child’s health and quality of life.

“Following recent programme expansion, newborn screening in Ireland now includes eleven conditions, including Severe Combined Immunodeficiency (SCID) and Spinal Muscular Atrophy (SMA). Testing for these 2 conditions began in April of this year. This expansion reflects our ongoing commitment to improving outcomes for children through early intervention.

“NSAC continues to consider other opportunities to expand newborn screening, and I look forward to receiving its further recommendations.”